Amplification ofMETmay identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752-Reference-Cited by-同舟云学术

Amplification ofMETmay identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Published:2006-02-06 Issue:7 Volume:103 Page:2316-2321
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:PNAS

Author:

Smolen Gromoslaw A.,Sordella Raffaella,Muir Beth,Mohapatra Gayatry,Barmettler Anne,Archibald Heidi,Kim Woo J.,Okimoto Ross A.,Bell Daphne W.,Sgroi Dennis C.,Christensen James G.,Settleman Jeffrey,Haber Daniel A.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference30 articles.

1. Addiction to Oncogenes--the Achilles Heal of Cancer

2. Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

3. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

4. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

5. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by 466 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network;Cancer Research Communications;2024-07-01

2. Correction for Smolen et al., Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752;Proceedings of the National Academy of Sciences;2024-06-13

3. MET Oncogene Targeting for Cancer Immunotherapy;International Journal of Molecular Sciences;2024-06-01

4. The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy;Pharmaceuticals;2024-03-30

5. Targeting MET in NSCLC: An Ever-Expanding Territory;JTO Clinical and Research Reports;2024-02